Connect with us

Technology

Artera Announces New AI Products and Harmony Platform Enhancements

Published

on

Two New AI Co-Pilots for Staff and Insights Offered Alongside 
Multiple Artera Harmony Platform Updates

SANTA BARBARA, Calif., Oct. 18, 2024 /PRNewswire/ — Artera, the leader in patient communications and trusted partner to more than 800 healthcare organizations, unveiled its latest AI products at the Artera Heartbeat Annual Customer Conference. With a mission to make healthcare number one in customer service, Artera announced two new AI-powered products — Artera Staff AI Co-Pilot and Artera Insights AI Co-Pilots — and significant updates to its award-winning patient communications platform, Artera Harmony.

These advancements aim to enhance patient experience, streamline healthcare operations and reduce administrative burden.

Artera Staff AI Co-Pilot: 
The Artera Staff AI Co-Pilot is designed using healthcare conversational data to assist administrative staff in managing patient communications faster and more accurately. The Staff AI Co-Pilot includes four skills to improve patient communications, increase response time and reduce administrative staff burden:

Translation: Provides culturally-relevant, real-time translation for inbound patient messages and outbound staff responses using the patient’s preferred language, ensuring the language is never a barrier to care.Predictive Text: Offers real-time text suggestions to help staff respond faster and more accurately to patient inquiries.Message Shortening: Helps rewrite longer messages, optimizing the messages for brevity and clarity, and reduces the number of overall messages sent to patients.Conversation Summaries: Summarizes patient conversations, making it easier for staff to summarize and document conversation history, including saving in Electronic Health Record (EHR) systems.Available now with Artera Harmony.

Artera Insights AI Co-Pilot:
Designed to help healthcare organizations make data-driven decisions, the Artera Insights AI Co-Pilot analyzes patient engagement data to provide actionable insights and timely recommendations. Currently available are:

Smart No-Show Reports: Using predictive analytics, Smart No-Show Reports identify patients at risk for missing appointments, offering healthcare providers the opportunity to intervene, engage and ideally improve care. Available now with Artera Harmony.

Coming in Q1 2025:

Smart No-Show Inbox: Expands on the Smart No-Show Reports by visually tagging within the Inbox anyone at risk for no-shows.Smart No-Show Trigger: Automate outreach to your at-risk patient appointments leveraging Artera Triggers.Next Best Actions: Provides a dashboard inside the Staff Console to surface key insights and suggested follow-up actions.

Artera Harmony Enhancements
Artera continues to enhance Artera Harmony, the award-winning patient communications SaaS platform, leveraged by today’s leading healthcare organizations. At Artera Heartbeat’24, several new Harmony features were unveiled: 

Flows: Enables multi-step conversation sequences while leveraging Natural Language Understanding (NLU) to automate patient engagement. New reusable Message Blocks, a Template Library and Flows reporting are now natively available within Harmony.Homepage with Next Best Actions: Artera homepage with clear “action items” for users, highlighting conversations needing attention and/or general insights from engagement data.Message Categorization: Uses Machine Learning models to categorize patient communications, powering new reports, new inbox filters and new home page insights.Native Value Reports: Analytics infrastructure built directly into Artera’s product, putting performance benchmarking, ROI reporting and greater reporting capabilities at the fingertips of staff users.Available now with Harmony.

Coming in Q1 2025:

Smart Inbox: An enhanced inbox UI/UX that allows staff to manage larger patient populations.

About Artera Heartbeat 
Artera Heartbeat is Artera’s premier customer conference for healthcare leaders seeking to transform patient communication. The event brings together industry experts, thought leaders and Artera customers to discuss the future of healthcare communication and showcase the latest innovations from Artera, Artera customers and Artera Marketplace Partners. Attendees benefit from hands-on workshops, visionary keynote sessions, affinity sessions with like-minded leaders and exclusive access to the latest product updates from Artera.

About Artera 
Artera is a SaaS digital health leader redefining patient communications. Artera is trusted by 800+ healthcare systems and federal agencies to facilitate approximately 2 billion communications annually, reaching 100+ million patients. The Artera platform integrates across a healthcare organization’s tech stack, EHRs and third-party vendors to unify, simplify and orchestrate digital communications into the patient’s preferred channel (texting, email, IVR, and webchat), in 109+ languages. The Artera impact: more efficient staff, more profitable organizations and a more harmonious patient experience.

Founded in 2015, Artera is based in Santa Barbara, California and has been named a Deloitte Technology Fast 500 company (2021, 2022, 2023), and ranked on the Inc. 5000 list of fastest-growing private companies for five consecutive years. Artera is a two-time Best in KLAS winner in Patient Outreach.

For more information, visit www.artera.io.

Forward-looking statements: These statements are based on current information and are subject to change without notice. They may not be accurate or reliable, and actual events may differ from those projected.

Disclaimer of responsibility: The company is not responsible for the correctness, completeness, or accuracy of the statements. The company also excludes claims for damages based on the press release.

Right to make changes: Artera reserves the right to make changes without notice in design, specifications, and models. The only warranty Artera makes is the express written warranty extended on the sale of its service(s) and/or product(s).

View original content to download multimedia:https://www.prnewswire.com/news-releases/artera-announces-new-ai-products-and-harmony-platform-enhancements-302280616.html

SOURCE Artera

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Barrel Energy Inc. Announces Full SEC Reporting Status, Strengthening Marketability and Positioning Company for Expansion in Renewable and Nutritional Energy Markets

Published

on

By

Barrel Energy Inc. (OTC: BRLL) A fully reporting company. Accelerates Growth Across Energy, Hospitality, and Sustainable Ventures, Driving Scalable Opportunities Worldwide.

LAS VEGAS, May 11, 2026 /PRNewswire/ — Barrel Energy Inc. (OTC: BRLL), an emerging diversified energy company focused on renewable energy and nutritional energy initiatives, today announced that the Company is now a fully reporting company with the U.S. Securities and Exchange Commission (“SEC”), marking a major turning point in the Company’s long term growth strategy and public market development.

Barrel Energy Inc. Announces Full SEC Reporting Status, Strengthening Marketability and positioning for Expansion.

“Our transition to becoming a fully reporting SEC company represents a significant milestone for Barrel Energy and an important step toward increasing the overall marketability and visibility of our stock,” said Jarmin Kaltsas. “We believe today’s market increasingly rewards transparency and compliance, and becoming fully reporting positions us to engage a wider audience of investors, strategic partners, and acquisition opportunities as we continue executing our long term growth strategy under the BRLL trading symbol.”

Management further stated that the Company plans to aggressively pursue growth initiatives intended to expand revenues, strengthen market presence, and enhance shareholder value through strategic business combinations, operational expansion, and scalable energy focused ventures.

About Barrel Energy Inc.

Barrel Energy Inc. (OTC: BRLL) is a diversified energy company focused on opportunities in renewable energy, and nutritional energy initiatives. The Company seeks to leverage strategic acquisitions, public market growth, and innovative energy solutions to create long term shareholder value.

Forward-Looking Statements:

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the Security and Exchange Commission.

Barrel Energy – 3859 S. Valley View Blvd, STE 2 #107, Las Vegas, NV, 89103 Tel- 888- 397-9114 Email- info@BRLLenergy.com Social Media-@BRLLenergy all platforms.

View original content:https://www.prnewswire.com/news-releases/barrel-energy-inc-announces-full-sec-reporting-status-strengthening-marketability-and-positioning-company-for-expansion-in-renewable-and-nutritional-energy-markets-302768505.html

SOURCE Barrel Energy, Inc.

Continue Reading

Technology

Legacy Launches $1M Study Advancing At-Home Semen Collection for Assisted Reproduction Technology

Published

on

By

NEW YORK, May 11, 2026 /PRNewswire/ — Legacy, the leading male fertility clinic and at-home sperm testing and cryopreservation platform, today announced the Sperm Study, a clinical research initiative backed by an R&D investment of over $1 million and designed to evaluate and optimize the use of at-home semen collection for assisted reproductive technologies (ART), including IVF and IUI.

Prospectively enrolling up to 250 participants across two phases, this study represents one of the most comprehensive investigations to date into how specimen shipment, handling, and cryopreservation impact sperm quality and is expected to set a new benchmark for scientific rigor in the rapidly growing field of at-home fertility testing. This study is being conducted in collaboration with IVF Academy USA.

Raising the bar for clinical evidence in at-home fertility care

To date, validation work in at-home semen collection has been limited in important ways. Studies have largely enrolled normozoospermic men only, relied on courier-transported rather than real-world-shipped specimens, and focused on short-term motility and concentration as primary endpoints.

Critical questions remain unanswered, particularly around how samples with varying quality perform under genuine end-to-end shipping conditions, and how those samples hold up in the contexts that matter most clinically: IVF and IUI. The Sperm Study is designed to close those gaps.

This multi-phase study will evaluate key sperm quality parameters including motility, DNA fragmentation, and post-thaw viability, while also validating the use of computer-aided semen analysis (CASA) as an alternative to basic manual semen analysis in the setting of mail-in semen analysis.

“With the increased utilization of at-home semen testing and cryopreservation, there is a critical need to ensure these specimens will perform adequately when used for assisted reproduction,” said Legacy’s Chief Medical Officer, Dr. Scott Lundy. “This study is designed to rigorously evaluate how at-home collection and transport impact sperm quality across a broad patient population and to translate those findings into improved protocols and optimized outcomes for both patients and providers.”

Sperm study design and scientific approach

The Sperm Study is a prospectively accruing cross-sectional study in which paired semen samples are analyzed across multiple timepoints and during the shipment process. Importantly, this study enrolls participants across a range of semen quality profiles — not solely normozoospermic men — and evaluates samples under genuine shipping conditions experienced by real specimens.

Key study components include direct comparison of CASA vs. manual analysis at baseline, evaluation of motility decline over time and in relation to shipment conditions, measurement of DNA fragmentation pre- and post-shipment and cryopreservation, assessment of post-thaw sperm viability and yield, and the development of predictive algorithms for IVF/IUI sample sufficiency.

The study will also examine how factors such as transit time, concentration, and storage conditions impact outcomes, with the goal of generating generalizable insights for clinical practice.

Multi-phase rollout

Phase 1 includes 100 participants and approximately 1,500 total assays, with expected completion in 2026. Phase 2, planned for later in 2026 and into 2027, will expand the study with additional participants, bringing the total to up to 250 to enable broader validation across a more diverse patient population.

Impact on clinical practice

Findings from the Sperm Study are expected to directly inform and improve specimen collection protocols for at-home use, shipping and handling standards for semen samples, cryopreservation practices, and clinical decision-making for IVF and IUI readiness.

By generating high-quality, controlled data across a clinically representative patient population, Legacy aims to provide fertility clinics, researchers, and patients with greater confidence in the use of mail-in semen testing and cryopreservation as part of standard reproductive care.

About Legacy

Legacy is the leading male fertility clinic in the United States, offering at-home semen analysis, sperm cryopreservation, and post-vasectomy testing. With a CLIA-certified, high-complexity andrology lab and one of the largest proprietary datasets in male reproductive health, Legacy is advancing access, data, and innovation in fertility care.

View original content to download multimedia:https://www.prnewswire.com/news-releases/legacy-launches-1m-study-advancing-at-home-semen-collection-for-assisted-reproduction-technology-302768508.html

SOURCE Give Legacy, Inc.

Continue Reading

Technology

Elks Award Nearly $5 Million in College Scholarships

Published

on

By

CHICAGO, May 11, 2026 /PRNewswire/ — The Elks National Foundation welcomed 900 students to the Elks family, awarding more than $4.9 million in scholarships to high school seniors. An Elks scholarship is more than financial aid; it’s an invitation to a network of service-minded peers and a promise that an Elks Lodge is always there with open arms.

Out of more than 23,000 applicants for the Most Valuable Student scholarship, the Top 20 scholars received $30,000 scholarships and an invitation to Chicago for the Leadership Weekend.

From April 30-May 3, the Leadership Weekend allowed scholars to get acquainted with their new Elks family through programming facilitated by current and former Elks scholars, team-building activities, and a service opportunity.

“Leadership Weekend is one of my greatest memories,” says Emily Cai, sponsored by Toccoa, Ga., Lodge No. 1820. “I had the privilege of meeting inspirational and disciplined individuals who motivated me to become the best version of myself. I am excited to see my future with the Elks family!”

A total of 480 runners-up received $4,000 Most Valuable Student scholarships.

Service is a tenet of the Elks, which is why it’s a requirement for recipients of the $6,000 Legacy Awards scholarship, which is exclusively for the children or grandchildren of Elks members. The new class of 400 scholars will serve with an Elks Lodge three times during the four years they receive the scholarship.

“This award means a great deal to me and my family,” says Kelly Butler, sponsored by Haverstraw, N.Y., Lodge No. 877. “Knowing that the Elks have invested in my future motivates me to continue working hard and striving toward my goals.”

To see a full list of the scholarship winners and to learn more about the Elks National Foundation’s scholarships, visit elks.org/scholars, follow the ENF on Instagram @ElksScholars, and like the ENF on Facebook @ElksNationalFoundation.

Contact: Elks National Foundation
Abbey Knupp | Manager, Communications
2750 N. Lakeview Ave. | Chicago, IL 60614-2256
773/755-4864 | AbbeyK@elks.org 

Helping Elks Build Stronger Communities

The Elks National Foundation, the charitable arm of the Benevolent and Protective Order of Elks, helps nearly 800,000 Elks and nearly 1,800 Lodges nationwide build stronger communities through programs that support youth, serve veterans, and meet needs in areas where Elks live and work. To learn more, visit elks.org/enf.

View original content to download multimedia:https://www.prnewswire.com/news-releases/elks-award-nearly-5-million-in-college-scholarships-302768507.html

SOURCE ELKS NATIONAL FOUNDATION, INC.

Continue Reading

Trending